Implementing an Opioid Risk Reduction Program in the Acute Comprehensive Inpatient Rehabilitation Setting.

OBJECTIVE: To describe the implementation and evaluation of an interdisciplinary quality improvement (QI) project to increase prescription of take-home naloxone (THN) to reduce risks associated with opioids for patients admitted to an acute inpatient rehabilitation unit. DESIGN: Prospective cohort quality improvement project. SETTING: Eighteen-bed acute comprehensive inpatient rehabilitation (ACIR) unit at a large academic institution. PARTICIPANTS: Patients admitted to ACIR between December 2015-November 2016 (N=788). INTERVENTIONS: An interdisciplinary QI model comprised of planning, education, implementation, and maintenance was used to implement a THN and opioid risk-reduction program involving provider and patient education. Analyses consisted of comparisons between baseline, early, and late phases of the project. MAIN OUTCOME MEASURES: (1) The proportion of eligible patients who received a prescription for naloxone upon discharge from ACIR; (2) the proportion of patients originally admitted to ACIR on opioids that were weaned off upon discharge. RESULTS: The adjusted odds of eligible patients being discharged from ACIR with a naloxone prescription during the late QI period were 7 (95% confidence interval [CI]: 3-21) times higher than during the early QI period (late QI period: 43%, 95% CI: 25%-63%; early QI period: 10%, 95% CI: 3%-28%; P<.001). For patients admitted on opioids, the adjusted odds of being weaned off opioids during the late QI period were 10 (95% CI: 4-25) times higher than during baseline (late QI period: 29%, 95% CI: 17%-45%; baseline: 4%, 95% CI: 1%-10%; P<.001). CONCLUSIONS: Implementation of a THN and opioid risk reduction QI project in an inpatient rehabilitation setting led to significantly more eligible patients receiving naloxone and more patients weaned off schedule II opioids.

The effect of ultraviolet radiation from a novel portable fluorescent lamp on serum 25-hydroxyvitamin D3 levels in healthy adults with Fitzpatrick skin types II and III.

BACKGROUND/PURPOSE: Ultraviolet (UV) B irradiation may provide a safe and effective method to treat vitamin D deficiency. The objective of this study was to assess the effectiveness of a novel Sperti D/UV-Fluorescent lamp in converting 7-dehydrocholesterol (7-DHC) to previtamin D(3) in vitro and in raising serum 25-hydroxyvitamin D(3) [25(OH)D(3) ] in healthy adults. METHODS: The lamp was assessed in vitro using a 7-DHC solution and a human skin sample. In a prospective cohort study, five healthy adults with skin types II and III were exposed to a 0.75 minimal erythemal dose of UV radiation over ≈ 9% of body surface area three times a week for 4 weeks. The main outcomes were percentage of conversion from 7-DHC to previtamin D(3) in vitro and changes in serum 25(OH)D(3) after irradiation in vivo. RESULTS: A dose response between UV irradiation time and conversion of 7-DHC to previtamin D(3) was seen in the 7-DHC solution and surgically obtained human skin. The subjects had a significant increase in mean 25(OH)D(3) from 18.4 ± 8.2 to 27.3 ± 7.6 ng/ml (P < 0.001) after 4 weeks of irradiation. No adverse events occurred. CONCLUSION: The Sperti D/UV-Fluorescent lamp is effective in converting 7-DHC to previtamin D(3) in vitro and in raising serum 25(OH)D(3) in healthy adults.